EA201500363A1 - Человеческие анти-vegfr-2/kdr-антитела - Google Patents
Человеческие анти-vegfr-2/kdr-антителаInfo
- Publication number
- EA201500363A1 EA201500363A1 EA201500363A EA201500363A EA201500363A1 EA 201500363 A1 EA201500363 A1 EA 201500363A1 EA 201500363 A EA201500363 A EA 201500363A EA 201500363 A EA201500363 A EA 201500363A EA 201500363 A1 EA201500363 A1 EA 201500363A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- vegfr
- kdr
- human anti
- monotherapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Изобретение относится к антителам, которые связываются с VEGFR-2. Антитела используются для лечения неопластических заболеваний, гиперпролиферативных процессов, ангиогенных нарушений и могут применяться в качестве монотерапии или в сочетании с другими агентами.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261710420P | 2012-10-05 | 2012-10-05 | |
PCT/US2013/063754 WO2014055998A1 (en) | 2012-10-05 | 2013-10-07 | Human anti-vegfr-2/kdr antibodies |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201500363A1 true EA201500363A1 (ru) | 2015-11-30 |
EA201500363A8 EA201500363A8 (ru) | 2016-04-29 |
EA032679B1 EA032679B1 (ru) | 2019-07-31 |
Family
ID=50435514
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990403A EA039595B1 (ru) | 2012-10-05 | 2013-10-07 | Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела |
EA201500363A EA032679B1 (ru) | 2012-10-05 | 2013-10-07 | Человеческие анти-vegfr-2/kdr-антитела |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990403A EA039595B1 (ru) | 2012-10-05 | 2013-10-07 | Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела |
Country Status (9)
Country | Link |
---|---|
US (2) | US10023640B2 (ru) |
EP (2) | EP2903647B1 (ru) |
JP (1) | JP6449772B2 (ru) |
CN (3) | CN105007939B (ru) |
CA (1) | CA2926386C (ru) |
EA (2) | EA039595B1 (ru) |
ES (2) | ES2781974T3 (ru) |
PL (1) | PL3685855T3 (ru) |
WO (1) | WO2014055998A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3204423A4 (en) | 2014-10-07 | 2018-03-28 | Kadmon Corporation, LLC | Human anti-vegfr-2/kdr antibodies |
KR20170135904A (ko) | 2015-04-14 | 2017-12-08 | 아카데미아 시니카 | 항-혈관신생 및 표적화된 암 치료법을 위한 항-vegfr2 인간 항체 |
JP2018528759A (ja) * | 2015-06-30 | 2018-10-04 | ヘンリアス バイオテック カンパニー リミテッド | 抗血管内皮増殖因子受容体2(vegfr2)抗体 |
KR101896882B1 (ko) * | 2015-11-30 | 2018-09-11 | 앱클론(주) | Vegfr2에 특이적으로 결합하는 항체 |
US20170233480A1 (en) * | 2015-12-31 | 2017-08-17 | Development Center For Biotechnology | Anti-vegfr antibody and uses thereof |
CN110840893A (zh) | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
CN113480653B (zh) * | 2021-08-06 | 2022-05-06 | 朱有建 | 一种含有γδT细胞的药物组合物在治疗癌症中的用途 |
KR20230109853A (ko) * | 2022-01-14 | 2023-07-21 | 주식회사 파멥신 | 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
CN1951939A (zh) | 2001-05-24 | 2007-04-25 | 伊莱利利公司 | 作为药物的新的吡唑衍生物 |
CA2478169C (en) * | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
DE60315677T2 (de) | 2002-09-17 | 2008-06-05 | Eli Lilly And Co., Indianapolis | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs |
MXPA05002982A (es) | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Derivados de triazol como inhibidores del factor de crecimiento transformante (tgf). |
US20060079680A1 (en) | 2002-11-22 | 2006-04-13 | Eli Lilly And Company Patent Division | Pyrazoloazepine compounds as pharmaceutical agents |
UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
US7405299B2 (en) | 2002-11-27 | 2008-07-29 | Eli Lilly And Company | Compounds as pharmaceutical agents |
CA2575791A1 (en) * | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
WO2006052568A2 (en) | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
EP1981538B1 (en) | 2005-12-30 | 2014-09-17 | Dyax Corporation | Metalloproteinase binding proteins |
US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
AR069501A1 (es) * | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
US8114968B2 (en) * | 2008-03-03 | 2012-02-14 | Dyax Corp. | Metalloproteinase-12 specific monoclonal antibody |
JP2012505900A (ja) * | 2008-10-14 | 2012-03-08 | ダイアクス コーポレーション | 全身性強皮症に伴う肺線維症の治療および予防のためのigf−ii/igf−iie結合タンパク質の使用 |
US20110125090A1 (en) * | 2008-11-13 | 2011-05-26 | Peyman Gholam A | Ophthalmic drug delivery system and method |
JP2012519732A (ja) | 2009-03-09 | 2012-08-30 | サーフェイス ロジックス,インコーポレイティド | Rhoキナーゼ阻害剤 |
US8128932B2 (en) * | 2009-08-17 | 2012-03-06 | Shanghai Aosaiersi Biotech Co., Ltd. | Anti-VEGFR monoclonal antibody, method of making and uses thereof |
CN101863980B (zh) * | 2009-12-31 | 2013-05-08 | 中国药科大学 | 全人源抗血管内皮细胞生长因子受体2单链抗体 |
BR112013000341A2 (pt) * | 2010-07-07 | 2017-09-26 | Tubitak | estruturas de anticorpos recombinantes ligando-se e bloqueando o crescimento da atividade vascular endotelial de fator 2 (vegfr-2/kdr) |
-
2013
- 2013-10-07 CA CA2926386A patent/CA2926386C/en active Active
- 2013-10-07 CN CN201380062991.XA patent/CN105007939B/zh active Active
- 2013-10-07 JP JP2015535881A patent/JP6449772B2/ja active Active
- 2013-10-07 EP EP13844157.1A patent/EP2903647B1/en active Active
- 2013-10-07 CN CN201811092472.9A patent/CN109160950B/zh active Active
- 2013-10-07 WO PCT/US2013/063754 patent/WO2014055998A1/en active Application Filing
- 2013-10-07 EA EA201990403A patent/EA039595B1/ru unknown
- 2013-10-07 ES ES13844157T patent/ES2781974T3/es active Active
- 2013-10-07 EA EA201500363A patent/EA032679B1/ru unknown
- 2013-10-07 CN CN202211207207.7A patent/CN116003600A/zh active Pending
- 2013-10-07 PL PL19219850.5T patent/PL3685855T3/pl unknown
- 2013-10-07 ES ES19219850T patent/ES2966030T3/es active Active
- 2013-10-07 US US14/431,954 patent/US10023640B2/en active Active
- 2013-10-07 EP EP19219850.5A patent/EP3685855B1/en active Active
-
2018
- 2018-06-14 US US16/008,744 patent/US10364291B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2014055998A1 (en) | 2014-04-10 |
EP2903647A1 (en) | 2015-08-12 |
EA032679B1 (ru) | 2019-07-31 |
CA2926386C (en) | 2021-11-09 |
JP2015533126A (ja) | 2015-11-19 |
US10364291B2 (en) | 2019-07-30 |
EP3685855C0 (en) | 2023-11-22 |
CA2926386A1 (en) | 2014-04-10 |
EP3685855B1 (en) | 2023-11-22 |
CN105007939B (zh) | 2018-10-19 |
JP6449772B2 (ja) | 2019-01-09 |
ES2781974T3 (es) | 2020-09-09 |
EA039595B1 (ru) | 2022-02-15 |
CN116003600A (zh) | 2023-04-25 |
CN105007939A (zh) | 2015-10-28 |
CN109160950B (zh) | 2022-10-04 |
CN109160950A (zh) | 2019-01-08 |
EP2903647A4 (en) | 2016-08-17 |
EA201500363A8 (ru) | 2016-04-29 |
US20150284464A1 (en) | 2015-10-08 |
ES2966030T3 (es) | 2024-04-18 |
EP2903647B1 (en) | 2020-01-01 |
EP3685855A1 (en) | 2020-07-29 |
US20180346579A1 (en) | 2018-12-06 |
EA201990403A1 (ru) | 2019-07-31 |
US10023640B2 (en) | 2018-07-17 |
PL3685855T3 (pl) | 2024-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
EA201990403A1 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
MX2015013170A (es) | Proteinas de union especificas duales dirigidas contra tnf alpha. | |
EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
EA201591806A1 (ru) | Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител | |
EA201391507A1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
MX2014008102A (es) | Inmunoglobulinas de dominio variable dual contra receptores. | |
MY163368A (en) | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use | |
EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
MX2017005977A (es) | Anticuerpos biespecificos y metodos de uso en oftalmologia. | |
EA201591973A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201500371A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ | |
EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
PH12015501360A1 (en) | Bmp-6 antibodies | |
UA118674C2 (uk) | Антитіло до igf-1r з елімінованою здатністю зв'язуватися з fcrn та його застосування для лікування судинних захворювань очей | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. |